scholarly journals Capsaicin 8% patch in trigeminal neuralgia: Case reports

2019 ◽  
Vol 12 (3) ◽  
Author(s):  
Maria Luz Canovas Martinez ◽  
Nuria Adan ◽  
Andrea Carballude ◽  
Laura Lamelas ◽  
Eva Villar ◽  
...  
Keyword(s):  
Trigeminal Neuralgia ◽  
Case Reports

scholarly journals Peripheral nerve field stimulation in medically refractory trigeminal neuralgia attributed to multiple sclerosis

2020 ◽  
pp. 1-7
Author(s):  
Johann Klein ◽  
Timo Siepmann ◽  
Gabriele Schackert ◽  
Tjalf Ziemssen ◽  
Tareq A. Juratli
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Trigeminal Neuralgia ◽  
Peripheral Nerve ◽  
Case Reports ◽  
Pain Severity ◽  
Field Stimulation ◽  
Peripheral Nerve Field Stimulation

OBJECTIVECase reports and small patient series have suggested peripheral nerve field stimulation (PNFS) as a treatment for refractory trigeminal neuralgia attributed to multiple sclerosis (MS). Here, the authors aimed to assess the effects of this technique on long-term pain severity.METHODSData were prospectively collected on patients with refractory trigeminal neuralgia attributed to MS who underwent PNFS between July 2013 and August 2017 at the authors’ neurosurgical department. Patients were evaluated before and after the first treatment as well as at follow-up at least twice a year. Patients underwent assessment of their pain severity using the Barrow Neurological Institute (BNI) Scale before treatment and at follow-up and were questioned about adverse events following cranial MRI performed after implantation of a permanent PNFS system.RESULTSEight patients (3 women) underwent PNFS trials and their median age was 61 years (IQR 73.75 − 46.5 years). Seven patients proceeded to permanent implantation of the stimulation system. At a median follow-up of 33 months (IQR 42 − 24 months), pain severity decreased from baseline to the last follow-up (BNI score decrease from V [IQR V − V] to III [IQR V − III], p = 0.054). Four patients experienced long-lasting benefit (at 48, 33, 24, and 15 months’ follow-up, respectively), while in 3 patients the treatment eventually failed after an initially successful period. One patient had an infection, requiring system removal and subsequent reimplantation. No other complications occurred. No adverse events were noted in the patients undergoing MRI postimplantation.CONCLUSIONSThis analysis indicates a possibly beneficial long-term effect of PNFS on refractory trigeminal neuralgia attributed to MS in some patients.

Trigeminal neuralgia in children: two case reports

2002 ◽  
Vol 26 (4) ◽  
pp. 309-310 ◽  
Author(s):  
Pedro G Lopes ◽  
Efigenio S Castro ◽  
Luiz Henrique G Lopes
Keyword(s):  
Trigeminal Neuralgia ◽  
Case Reports

Treatment-Resistant Trigeminal Neuralgia: Case Reports

2007 ◽  
Vol 19 (3) ◽  
pp. 155-158 ◽  
Author(s):  
George W. Kukurin ◽  
Michael Cutitta
Keyword(s):  
Trigeminal Neuralgia ◽  
Case Reports ◽  
Treatment Resistant

Stimulation of the Gasserian Ganglion for the Treatment of Refractory Trigeminal Neuralgia. Two Case Reports

2020 ◽  
pp. 33-38
Author(s):  
Shafik Boyaji
Keyword(s):  
Trigeminal Neuralgia ◽  
Peripheral Nerve ◽  
Pulse Generator ◽  
Case Reports ◽  
Functional Improvement ◽  
Surgical Approaches ◽  
Gasserian Ganglion ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator ◽  
Stimulation Of

Background: Treatment of trigeminal neuralgia (TN) can be challenging for many physicians; patients who do not respond to conventional treatments and traditional surgical approaches often continue to suffer with pain. The peripheral nerve stimulator has been used to treat many chronic pain conditions, but few reports exist about its use to treat refractory TN through the stimulation of the Gasserian ganglion (GG). Case Report: We present 2 cases of patients with refractory TN who failed conventional medical and surgical management. Both patients were suitable candidates for a trial of peripheral nerve stimulation of the GG, both patients had positive results with the trials, and proceeded with permanent placement of the GG stimulator. In both cases we used deep brain stimulator leads, which were placed under fluoroscopy guidance through the foramen ovale onto the GG, and tunneled through the postauricular area to a pocket in the upper chest wall under the clavicle for the implantable pulse generator. Both of our patients experienced a significant symptomatic and functional improvement in their symptoms. The second patient was successfully weaned off her opioid pain medications after 6 months of treatment. Conclusion: Percutaneous stimulation of the GG is a promising technique for the treatment of refractory trigeminal neuropathic pain. More studies and experiences with this technique are needed to better demonstrate the efficacy and the safety profile, which potentially could allow this procedure to be considered ahead of the more invasive neurodestructive surgical treatments. Key words: Trigeminal neuralgia, Gasserian ganglion, peripheral nerve stimulator

scholarly journals OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data

2015 ◽  
Vol 73 (10) ◽  
pp. 877-884 ◽  
Author(s):  
Pedro A. Kowacs ◽  
Marco A. T. Utiumi ◽  
Fábio A. Nascimento ◽  
Elcio J. Piovesan ◽  
Helio A. G. Teive
Keyword(s):  
Side Effects ◽  
Trigeminal Neuralgia ◽  
Case Reports ◽  
Therapeutic Option ◽  
Case Series ◽  
Neurosurgical Procedures ◽  
Open Label ◽  
Randomized Controlled ◽  
Pain Syndromes ◽  
Proven Efficacy

Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.

Sign in / Sign up

Export Citation Format

Share Document